Yuliya Kitsel
Research Subjects
Yuliya Kitsel has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Assen S. Kirov
Medical Physics, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, New York, 10065, United States
2 shared publications - Constantinos T. Sofocleous
Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications Elena N. Petre
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
2 shared publicationsJia Wu
2 shared publicationsMahdi Zirakchian Zadeh
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
2 shared publications- Vlasios S. Sotirchos
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
2 shared publications
Latest Publications
- 20 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (8) , 22-32
Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center
- 20 August 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (8) , 22-32
Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center
- Open Access
- 11 May 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 3 (2)
Immune-related Pulmonary Granulomas Mimicking Metastatic Lesions in a Lung Cancer Patient
Immune checkpoint inhibitors are widely used in non–small cell lung cancer but can cause immune-related adverse events. FDG-avid pulmonary granulomas are unusual and may be mistaken for metastases. We report a 72-year-old man with mucinous adenocarcinoma treated with immunotherapy who developed new FDG-avid, well-circumscribed, round lung nodules, initially suspected as metastases. Biopsy revealed non-necrotizing granulomas, and the nodules regressed without corticosteroids. This case highlights a diagnostic pitfall during immunotherapy, where immune-related granulomas can resemble disease progression. Clinician awareness is essential to avoid unnecessary interventions and ensure appropriate management.
- 11 May 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine Open
- Vol. 3 (2)
Open AccessImmune-related Pulmonary Granulomas Mimicking Metastatic Lesions in a Lung Cancer Patient
Immune checkpoint inhibitors are widely used in non–small cell lung cancer but can cause immune-related adverse events. FDG-avid pulmonary granulomas are unusual and may be mistaken for metastases. We report a 72-year-old man with mucinous adenocarcinoma treated with immunotherapy who developed new FDG-avid, well-circumscribed, round lung nodules, initially suspected as metastases. Biopsy revealed non-necrotizing granulomas, and the nodules regressed without corticosteroids. This case highlights a diagnostic pitfall during immunotherapy, where immune-related granulomas can resemble disease progression. Clinician awareness is essential to avoid unnecessary interventions and ensure appropriate management.
- 24 April 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (7) , 1012-1021.e1
Histopathologic Changes after Yttrium-90 Radioembolization of Colorectal Liver Metastases: A Pilot Feasibility Study
- 24 April 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (7) , 1012-1021.e1
Histopathologic Changes after Yttrium-90 Radioembolization of Colorectal Liver Metastases: A Pilot Feasibility Study
- 10 January 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (4) , 523-532.e1
Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4–8-Week Postablation Assessment
- 10 January 2024
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 35 (4) , 523-532.e1
Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4–8-Week Postablation Assessment